MedTrace Logo

A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults

NCT07423286 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-02-20

No results posted yet for this study

Summary

For this study, the study medicine has been specially prepared to contain radiolabeled carbon \[14C\]. \[14C\] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study medicine does not change how the medicine works but helps to see how the medicine appears in the blood, urine, and stool after it is given. This type of study is called a radiolabeled study.

The purpose of this radiolabeled study is to learn how a certain amount of \[14C\] PF-07248144 is taken up into the bloodstream and removed from the body.

The study is seeking participants who are:

* females who cannot have children, or males
* 18 years of age or older
* confirmed to be healthy based on medical and physical tests.
* weigh more than 50 kilograms (kg) and have a body mass index of 18 to 32 kg per meter squared.

The study consists of two parts. In part one, all participants will receive one full dose of \[14C\]PF-07248144 by mouth. Part two will begin at least 28 days after the dose in part one. In part two, participants will receive one full dose of PF-07248144 by mouth and one small dose of \[14C\] PF-07248144 by intravenous (IV) infusion. IV infusion will be directly injected into the veins.

To understand how the medicine is processed in the body, samples of blood, urine, feces, and vomit (if any) will be collected after each dose is given. This will help understand:

* How much PF-07248144 is taken up into the bloodstream when taken by mouth compared to the dose given by IV
* How the body removes it from the blood steam.

Participants will take part in the study for about 15 weeks, including evaluation at the start and follow-up period.

Conditions

  • Healthy Adult Participants

Interventions

DRUG

Oral [14C] PF-07248144

A single oral dose of \[14C\] PF-07248144 will be administered as an extemporaneous suspension in Period 1

DRUG

Oral unlabeled PF-07248144

A single oral dose of unlabeled PF-07248144 will be administered as tablets in Period 2

DRUG

IV [14C] PF-07248144

A single IV infusion of \[14C\] PF-07248144 will be administered at the approximate Tmax after administration of the unlabeled oral dose of PF-07248144 in Period 2

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-13
Primary Completion
2025-12-28
Completion
2026-01-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07423286 on ClinicalTrials.gov